

July 30, 2012



Navidea Biopharmaceuticals Second Quarter 2012 Earnings and Business Update Conference Call Invitation

Conference Call Scheduled for 8:00 AM EDT, Tuesday, August 7th

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the second quarter of 2012 on Monday, August 6, 2012 after market close. The announcement of results will be followed by a conference call with the investment community, Tuesday, August 7, 2012 at 8:00 AM EDT.

Navidea's President and CEO, Dr. Mark Pykett, Executive Vice President and Chief Business Officer, Dr. Thomas Tulip, and CFO, Brent Larson, will provide a development and business update and will discuss the Company's financial results for the second quarter of 2012 during the conference call. The conference call can be accessed as follows:

CONFERENCE CALL INFORMATION

TO PARTICIPATE LIVE:

Date: August 7, 2012

Time: 8:00 AM EDT

TO LISTEN TO A REPLAY:

Available until: August 21, 2012

Toll-free (U.S.) Dial in # : (877) 660-6853

International Dial in # : (201) 612-7415

Toll-free (U.S.) Dial in # : (877) 407-8033

International Dial in # : (201) 689-8033 Replay passcode:

Account # 286

Conference ID #: 398463

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek[®], AZD4694 and RIGScan[™] – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-

making and ultimately patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals, Inc.

Brent Larson, 614-822-2330

Sr. VP & CFO

Source: Navidea Biopharmaceuticals, Inc.